<- Go Home
Veracyte, Inc.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Market Cap
$2.9B
Volume
912.8K
Cash and Equivalents
$219.5M
EBITDA
$63.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$338.0M
Profit Margin
70.55%
52 Week High
$47.32
52 Week Low
$22.61
Dividend
N/A
Price / Book Value
2.36
Price / Earnings
109.42
Price / Tangible Book Value
8.20
Enterprise Value
$2.6B
Enterprise Value / EBITDA
34.91
Operating Income
$40.8M
Return on Equity
2.24%
Return on Assets
1.98
Cash and Short Term Investments
$320.7M
Debt
$50.6M
Equity
$1.2B
Revenue
$479.1M
Unlevered FCF
$75.4M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium